Mitsui Toatsu Chemicals, Incorporated

Mitsui Petrochemical Industries, Ltd.

Mitsui Pharmaceuticals, Inc.

Mect Corporation

Mitsui Toatsu Kagaku Kabushiki Kaisha

Kainos Laboratories, Inc.

Mitsui Toatsu Kagaki Kabushiki Kaisha

Mitsui Toatsu Kaguku Kabushiki Kaisha

Akira Awaya

Takuo Nakano

Yutaka Okazaki

Ikuo Tomino

Mikio Kumakura

Hiroshi Tokuda

Isao Sakano

Kazutoshi Horikomi

Hiroshi Kawazura

Tatsuro Yokoyama

Seitaro Kajiya

Akira Mizuchi

Takumi Kitahara

Hisashi Kobayashi

Yusaku Ishizuka

Tadayuki Sasaki

Noriaki Kihara

Keiichi Yokoyama

Shoichiro Ozaki

Joji Kamiya

Hayao Abe

Yutaka Watanabe

Tsuneji Suzuki

Yoshiyuki Kanai

Takafumi Kitano

Hiroyasu Ohno

Masaharu Ishiguro

Mitsuyuki Takesue

Koji Kato

Masahiko Maruyama

Makoto Hirayama

Toshihiko Ito

Tomoya Ogawa

Masayoshi Ito

Ken Ikeda

Shoji Yoshimura

Masaaki Numata

Yoshitaka Nagai

Makoto Tanaka

Keiichi Hiramatsu

Takashi Nishina

Shohei Shibayama

Masaaki Ishii

Shintaro Araki

Shigeru Isayama

Kazuyuki Watanabe

Yoshitsugu Yamada

Shiyoichiro Miyahara

Kunio Sannohe

Kanji Yoshihara

Tamotsu Minami

Hiroie Ohno

Tsukasa Hayashi

Masato Hirata

Yuichiro Kokubun

Toshikazu Yamanouchi

Kojun Torigoe

Ken E Tan

Fumiaki Ito

Kozi Kato

Kajiya Seitaro

Teruyo Ito

Sakae Saruta

Sannohe, Kunio

Method of identifying methicillin-resistant Staphylococcus aureus or

The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or modification of biological activities of a growth and/or differentiation factor, a growth hormone or a cytokine. This invention also provides a wound-healing method, which comprises as an active ingredient a compound of the following formula (1) or formula (2) found to be active by the screening method. ##STR1##

Method for healing compromised tissues using pyrimidine derivatives

Pyrimidine compound and pharmaceutically acceptable salts thereof

A medicament for prevention and remedy of diseases caused by the infection of viruses is disclosed, which is characterized by containing as an effective ingredient thereof a nonapeptide having the following amino acid configuration: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn or an ester and an amide at the carboxyl group of the C-terminal of the asparagine or a pharmacologically acceptable salt thereof.

Method of treating disease caused by the infection of virus

This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.

Pyrimidines and pharmaceutically acceptable salts thereof useful in

Disclosed herein are phosphoric acid esters of myoinositol, which are represented by the following general formula (I): ##STR1## and their salts, as well as a preparation process thereof. The myoinositol derivatives can each be obtained by causing a phosphorylating agent to act on a myoinositol derivative substituted with catalytic reduction removable substituent groups at the positions other than those desired to be substituted by phosphoric acid residual groups and then catalytically reducing the thus-phosphorylated myoinositol.

Myoinositol derivatives and preparation process thereof

Medicament for prevention and remedy of diseases of the pancreas and

2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological deseases.

Pyrimidines and their pharmaceutical acceptable salts, and their use as

Inositol derivative and method for preparing same

B cell differentiation factor which acts on B cells and participates in their differentiation into antibody-producing cells is produced by an established cell line.

Established cell line

Amine represented by the following formula (1), or their acid addition salts or their quaternary ammonium salts. ##STR1## The amines of formula (1) or their pharmaceutically acceptable acid addition salts or quaternary ammonium salts are useful for the treatment and prevention of heart diseases of animals, particularly arrhythima, myocardial infarction, angina pectoris and heart failure and psychoneurological diseases.

Coumaran group containing amine compounds and their acid addition salts

2,6-di-, 2,4,6-, 2,5,6-tri- or 2,4,5,6-tetra-substituted pyrimidines, and 2,6-di-substituted pyridines. These compounds are useful for treatment of neurological diseases.

2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines,

A novel established cell line, KML.sub.1-7, obtained by collecting lymphoid cells from an animal with autoimmune disease, culturing them in a culture medium containing the supernatant of a culture in which lymphoid cells of animal origin have been grown in the presence of a mitogen, and continuing the culture for a period of 8 months until the cells are able to grow in the absence of the aforesaid supernatant. This established cell line has the following properties.

Established cell line, KML.sub.1-7, which produces B-cell

A sialic acid-bonded octapeptide represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or an acetyl group; and R' represents a lower alkyl group, an aralkyl group, a hydrogen atom or an alkali metal atom, is herein disclosed. The peptide chain of the sialic acid-bonded octapeptide is constituted by 8 amino acid molecules on the C-terminus side of FTS and the compounds represented by formula (I) can be obtained by bonding sialic acid to the amino terminus of the peptide chain according to condensation. These octapeptides show excellent physiological activity comparable to FTS and a half life in blood longer than that of FTS and it is expected that the affinity of the peptide to lymphocytes is also enhanced. Thus they can effectively be used as medicines for treating the lowering and abnormality of functions of the thymus.

Sialic acid-bonded octapeptide and preparation thereof

Therapeutic agent for neurological diseases

Growing community of inventors

Yokohama, Japan

Akira Awaya